Daniel Rinewalt1, Patrick M McCarthy2, Sukit Chris Malaisrie1, Paul W M Fedak3, Adin-Cristian Andrei1, Jyothy J Puthumana4, Robert O Bonow4. 1. Division of Cardiac Surgery, Martha and Richard Melman Family Bicuspid Aortic Valve Program, Bluhm Cardiovascular Institute, Department of Surgery, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Ill. 2. Division of Cardiac Surgery, Martha and Richard Melman Family Bicuspid Aortic Valve Program, Bluhm Cardiovascular Institute, Department of Surgery, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: pmccart@nmh.org. 3. Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada. 4. Division of Cardiology, Martha and Richard Melman Family Bicuspid Aortic Valve Program, Bluhm Cardiovascular Institute, Department of Surgery, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Abstract
OBJECTIVE: Bicuspid aortic valve (BAV) disease is associated with aortic dilatation and aneurysm (AN) formation. The American College of Cardiology/American Heart Association (ACC/AHA) 2006 guidelines recommend replacement of the ascending aorta for an aortic diameter (AD)> 45 mm in patients undergoing aortic valve replacement (AVR). We evaluated the outcomes of AVR and AVR with aortic replacement (AVR/AN). METHODS: We retrospectively reviewed (2004-2011) the data from 456 patients with BAV and compared the morbidity and mortality between the AVR and AVR/AN groups and 3 subgroups: AVR with an AD<45 mm; AVR/AN with an AD of 45 to 49 mm; and AVR/AN with an AD of ≥50 mm. Propensity score matching was used to reduce bias. RESULTS: Of the 456 patients, 250 (55%) underwent AVR and 206 (45%) AVR/AN, with 98% compliance with the current guidelines. The overall 30-day mortality was 0.9%. The AVR AD<45-mm group had adjusted short- and medium-term survival similar to that of the AVR/AN AD 45- to 49-mm and AVR/AN AD≥50-mm groups, with a 30-day mortality of 0.8%, 0%, and 1.9%, respectively (P=.41). The propensity score-matched AVR/AN AD≥50-mm group had significantly greater rates of reintubation than either the AVR AD<45-mm (P=.012) or AVR/AN AD 45- to 49-mm (P=.04) group and greater rates of prolonged ventilation (P=.022) than the AVR AD<45-mm group. No significant differences were found in reoperation or myocardial infarction among the subgroups. CONCLUSIONS: In patients with undergoing AVR, no increase was seen in morbidity or mortality when adding aortic replacement with an AD of 45 to 49 mm, in accordance with the 2006 ACC/AHA guidelines, although the AVR/AN AD≥50-mm group had a greater risk of respiratory complications. Our findings indicate that compliance with the ACC/AHA guidelines is safe in select centers.
OBJECTIVE: Bicuspid aortic valve (BAV) disease is associated with aortic dilatation and aneurysm (AN) formation. The American College of Cardiology/American Heart Association (ACC/AHA) 2006 guidelines recommend replacement of the ascending aorta for an aortic diameter (AD)> 45 mm in patients undergoing aortic valve replacement (AVR). We evaluated the outcomes of AVR and AVR with aortic replacement (AVR/AN). METHODS: We retrospectively reviewed (2004-2011) the data from 456 patients with BAV and compared the morbidity and mortality between the AVR and AVR/AN groups and 3 subgroups: AVR with an AD<45 mm; AVR/AN with an AD of 45 to 49 mm; and AVR/AN with an AD of ≥50 mm. Propensity score matching was used to reduce bias. RESULTS: Of the 456 patients, 250 (55%) underwent AVR and 206 (45%) AVR/AN, with 98% compliance with the current guidelines. The overall 30-day mortality was 0.9%. The AVR AD<45-mm group had adjusted short- and medium-term survival similar to that of the AVR/AN AD 45- to 49-mm and AVR/AN AD≥50-mm groups, with a 30-day mortality of 0.8%, 0%, and 1.9%, respectively (P=.41). The propensity score-matched AVR/AN AD≥50-mm group had significantly greater rates of reintubation than either the AVR AD<45-mm (P=.012) or AVR/AN AD 45- to 49-mm (P=.04) group and greater rates of prolonged ventilation (P=.022) than the AVR AD<45-mm group. No significant differences were found in reoperation or myocardial infarction among the subgroups. CONCLUSIONS: In patients with undergoing AVR, no increase was seen in morbidity or mortality when adding aortic replacement with an AD of 45 to 49 mm, in accordance with the 2006 ACC/AHA guidelines, although the AVR/AN AD≥50-mm group had a greater risk of respiratory complications. Our findings indicate that compliance with the ACC/AHA guidelines is safe in select centers.
Authors: Charles M Wojnarski; Lars G Svensson; Eric E Roselli; Jay J Idrees; Ashley M Lowry; John Ehrlinger; Gösta B Pettersson; A Marc Gillinov; Douglas R Johnston; Edward G Soltesz; Jose L Navia; Donald F Hammer; Brian Griffin; Maran Thamilarasan; Vidyasagar Kalahasti; Joseph F Sabik; Eugene H Blackstone; Bruce W Lytle Journal: Ann Thorac Surg Date: 2015-07-22 Impact factor: 4.330
Authors: Alexander P Nissen; Van Thi Thanh Truong; Bader A Alhafez; Jyothy J Puthumana; Anthony L Estrera; Simon C Body; Siddharth K Prakash Journal: J Thorac Cardiovasc Surg Date: 2019-08-22 Impact factor: 5.209
Authors: Michael A Borger; Paul W M Fedak; Elizabeth H Stephens; Thomas G Gleason; Evaldas Girdauskas; John S Ikonomidis; Ali Khoynezhad; Samuel C Siu; Subodh Verma; Michael D Hope; Duke E Cameron; Donald F Hammer; Joseph S Coselli; Marc R Moon; Thoralf M Sundt; Alex J Barker; Michael Markl; Alessandro Della Corte; Hector I Michelena; John A Elefteriades Journal: J Thorac Cardiovasc Surg Date: 2018-08 Impact factor: 5.209
Authors: Erin E Crawford; Patrick M McCarthy; S Chris Malaisrie; Jyothy J Puthumana; Joshua D Robinson; Michael Markl; Menghan Liu; Adin-Cristian Andrei; David G Guzzardi; Jane Kruse; Paul W M Fedak Journal: J Clin Med Date: 2020-05-05 Impact factor: 4.241
Authors: Erin E Crawford; Patrick M McCarthy; S Chris Malaisrie; Christopher K Mehta; Jyothy J Puthumana; Joshua D Robinson; Michael Markl; Robert O Bonow; Paul W M Fedak Journal: Ann Cardiothorac Surg Date: 2022-07
Authors: David G Guzzardi; Alex J Barker; Pim van Ooij; S Chris Malaisrie; Jyothy J Puthumana; Darrell D Belke; Holly E M Mewhort; Daniyil A Svystonyuk; Sean Kang; Subodh Verma; Jeremy Collins; James Carr; Robert O Bonow; Michael Markl; James D Thomas; Patrick M McCarthy; Paul W M Fedak Journal: J Am Coll Cardiol Date: 2015-08-25 Impact factor: 24.094